IF1 attenuated HCC cell sensitivity to sorafenib therapy after insufficient RFA through NF-κB signaling and indicated poor disease free survival in patients with HCC after sorafenib treatment. This evidence concerns the gene NFKB1 and hepatocellular carcinoma.